Blood Res.  2014 Jun;49(2):127-129. 10.5045/br.2014.49.2.127.

A case of chronic myeloid leukemia with features of essential thrombocythemia in peripheral blood and bone marrow

• Byun YJ
• Park BB
• Lee ES
• Choi KS
• Lee DS

• KMID: 2172809
• DOI: http://doi.org/10.5045/br.2014.49.2.127

Abstract

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by overproduction of myeloid white blood cells. Philadelphia chromosome is an essential finding for CML diagnosis. Generally, a clinical diagnosis of essential thrombocythemia (ET) can be established from isolated marked thrombocytosis in peripheral blood. However, Philadelphia chromosome-positivity or bcr/abl rearrangement with isolated thrombocytosis should be diagnosed as CML, not ET, according to World Health Organization diagnostic criteria. Therefore, CML should not be excluded before confirming the presence of the Philadelphia chromosome or bcr/abl rearrangement in cases of isolated thrombocytosis in peripheral blood. We report a case of CML with clinical features of ET in a patient successfully treated with imatinib.

Keyword

Chronic myeloid leukemia; Philadelphia chromosome; Essential thrombocythemia

MeSH Terms

Bone Marrow*
Diagnosis
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*
Leukocytes
Philadelphia Chromosome
Thrombocythemia, Essential*
Thrombocytosis
World Health Organization
Imatinib Mesylate

Figure

• 

  Fig. 1 Thrombocytosis without obvious morphologic abnormalities of the white blood cells and erythrocytes in peripheral blood smear (Wright Giemsa stain, ×400).

• 

  Fig. 2 Bone marrow core biopsy sample showing hypercellular bone marrow for age with expanded myelopoiesis and small megakaryocytes with decreased nuclear lobation (H&E stain, ×200).

Reference

1. Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999; 340:1330–1340. PMID: 10219069.

2. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007; 110:1092–1097. PMID: 17488875.

3. Kwong YL, Chiu EK, Liang RH, Chan V, Chan TK. Essential thrombocythemia with BCR/ABL rearrangement. Cancer Genet Cytogenet. 1996; 89:74–76. PMID: 8689617.

4. Stoll DB, Peterson P, Exten R, et al. Clinical presentation and natural history of patients with essential thrombocythemia and the Philadelphia chromosome. Am J Hematol. 1988; 27:77–83. PMID: 3422539.

5. Emilia G, Marasca R, Zucchini P, et al. BCR-ABL rearrangement is not detectable in essential thrombocythemia. Blood. 2001; 97:2187–2189. PMID: 11286226.

6. Michiels JJ, Berneman Z, Schroyens W, et al. Philadelphia (Ph) chromosome-positive thrombocythemia without features of chronic myeloid leukemia in peripheral blood: natural history and diagnostic differentiation from Ph-negative essential thrombocythemia. Ann Hematol. 2004; 83:504–512. PMID: 15164229.

7. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355:2408–2417. PMID: 17151364.

8. Damaj G, Delabesse E, Le Bihan C, et al. Typical essential thrombocythaemia does not express bcr-abelson fusion transcript. Br J Haematol. 2002; 116:812–816. PMID: 11886385.

9. Savage DG, Antman KH. Imatinib mesylate-a new oral targeted therapy. N Engl J Med. 2002; 346:683–693. PMID: 11870247.

10. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003; 348:994–1004. PMID: 12637609.